Balloon Prophylaxis of Aneurysmal Vasospasm

NCT ID: NCT00282893

Last Updated: 2017-02-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

170 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-10-31

Study Completion Date

2006-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if early transluminal ballooning of the major cerebral arteries prevents severe vasospasm and improves neurological outcome in patients with Fisher Grade III aneurysmal subarachnoid hemorrhage.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Aneurysmal subarachnoid hemorrhage (SAH) afflicts over 30,000 patients a year in the United States. Fifteen percent of those who survive the initial bleeding die or suffer disabilities because of delayed ischemic deficit (stroke) due to vasospasm. Vasospasm is a condition in which the arteries in the brain constrict, not allowing sufficient blood flow and oxygenation. Research on the pharmacological prevention and treatment of vasospasm has resulted in only minimal improvement for this problem.

Transluminal ballooning is a procedure that opens blood vessels, allowing blood flow and oxygen to get to the brain more easily. Researchers believe that this dilation of the blood vessels lasts for at least 7 days. This procedure is used to treat severe vasospasm although it is not commonly used to prevent vasospasm. The purpose of this trial is to find out if this procedure, performed immediately after the aneurysm is secured, prevents spasm in the brain and improves patient outcome.

Eligible SAH patients whose aneurysm has been repaired by neurosurgical or endovascular procedure and who are enrolled in the study will be randomized to receive either the prophylactic transluminal ballooning procedure or to receive standard care, which includes currently existing therapies for the treatment of vasospasm.

Participants will be asked to return for follow-up examinations at 3 and 6 months to evaluate recovery using a standardized outcome scale.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aneurysm Vasospasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

pTBA

Prophylactic Transluminal Ballooning Angioplasty

Group Type EXPERIMENTAL

transluminal ballooning

Intervention Type PROCEDURE

Control

currently existing therapies for the treatment of vasospasm

Group Type ACTIVE_COMPARATOR

currently existing therapies for the treatment of vasospasm

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

transluminal ballooning

Intervention Type PROCEDURE

currently existing therapies for the treatment of vasospasm

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Fisher grade III hemorrhage
* Documented ruptured cerebral aneurysm via angiography, CT angiogram or any other acceptable neuroradiologic means
* Ruptured aneurysm(s) secured
* Ballooning available \< 96 hours post SAH

Exclusion Criteria

* Vasospasm prior to randomization
* Interventionalist unavailable
* Patient outside the 96 hour window for ballooning
* Enrolled in competing trial
* Unsecured aneurysms (symptomatic or asymptomatic) that are in the location where the ballooning procedure would occur
* Medical conditions known that would effect mortality / morbidity
* Severe Cerebrovascular atherosclerosis
* \> 16 years old.
Minimum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

Sponsor Role collaborator

University of California, Davis

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jan Paul Muizelaar, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Professor and Chairman, Department of Neurological Surgery, University of California, Davis

Jonathan Hartman, MD

Role: PRINCIPAL_INVESTIGATOR

Interventional Neuroradiologist, University of California, Davis

Marike Zwienenberg, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, Davis

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Coordinating Center: University of California, Davis Medical Center, Department of Neurological Surgery

Sacramento, California, United States

Site Status

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status

University of Washington - Harborview Medical Center

Seattle, Washington, United States

Site Status

University of Toronto

Toronto, Ontario, Canada

Site Status

University Medical Center Utrecht, Trialbeureau Neurodivisie, Heidelberglaan 100

Utrecht, , Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Netherlands

References

Explore related publications, articles, or registry entries linked to this study.

Zwienenberg-Lee M, Hartman J, Rudisill N, Madden LK, Smith K, Eskridge J, Newell D, Verweij B, Bullock MR, Baker A, Coplin W, Mericle R, Dai J, Rocke D, Muizelaar JP; Balloon Prophylaxis for Aneurysmal Vasospasm (BPAV) Study Group. Effect of prophylactic transluminal balloon angioplasty on cerebral vasospasm and outcome in patients with Fisher grade III subarachnoid hemorrhage: results of a phase II multicenter, randomized, clinical trial. Stroke. 2008 Jun;39(6):1759-65. doi: 10.1161/STROKEAHA.107.502666. Epub 2008 Apr 17.

Reference Type RESULT
PMID: 18420953 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01NS038484

Identifier Type: NIH

Identifier Source: secondary_id

View Link

200311385

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.